Trials / Recruiting
RecruitingNCT07413055
Comparative Efficacy Of 4 mg VS. 8 mg Submucosal Dexamethasone In Postoperative Pain Management After Dental Implant Surgery: A Randomized Double-Blind Controlled Clinical Trial
Comparative Efficacy of 4 mg vs. 8 mg Submucosal Dexamethasone in Postoperative Pain Management After Dental Implant Surgery: A Randomized Double-Blind Controlled Clinical Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 138 (estimated)
- Sponsor
- Oman Ministry of Health · Other Government
- Sex
- All
- Age
- 21 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to compare the effectiveness of 4mg and 8mg dexamethasone administered submucosally in reducing postoperative pain after dental implant surgery. Participants will be randomly assigned to receive either 4mg dexamethasone, 8mg dexamethasone, or a placebo (normal saline) at the surgical site. Later, postoperative pain will be assessed using a Visual Analog Scale at 6 hours after the surgery and daily for the next 6 days. Also the number of pain-relief tablets consumed after the surgery will be recorded. Preoperative anxiety will be assessed using Generalized Anxiety Disorder-7 (GAD-7) questionnaire to assess its association with postoperative pain scores. The results of this study will help determine the optimal dose of dexamethasone that is effective for postoperative pain control following dental implant surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexamethasone 4 Mg/mL Injectable Solution | Syringe will be concealed. Submucosal injection will be adjacent to the surgical site in the buccal vestibule |
| DRUG | Dexamethasone 8Mg Solution for Injection | Syringe will be concealed. Submucosal injection will be adjacent to the surgical site in the buccal vestibule |
| DRUG | Saline (NaCl 0,9 %) (placebo) | Syringe will be concealed. Submucosal injection will be adjacent to the surgical site in the buccal vestibule |
Timeline
- Start date
- 2026-03-25
- Primary completion
- 2026-11-15
- Completion
- 2026-12-01
- First posted
- 2026-02-17
- Last updated
- 2026-03-30
Locations
1 site across 1 country: Oman
Source: ClinicalTrials.gov record NCT07413055. Inclusion in this directory is not an endorsement.